Pfizer's 0.65% Rally on 85th Most Active Day Navigates Vaccine Hopes and Cost Cuts Amid Patent Looming Challenges

On August 29, 2025, Pfizer (PFE) rose 0.65% with a trading volume of $0.92 billion, ranking 85th in market activity. The stock’s performance was influenced by recent developments in its vaccine portfolio and strategic cost initiatives.

Pfizer received FDA approval for updated COVID-19 vaccines, though distribution will be restricted to high-risk groups. This update aligns with seasonal demand but may limit broader market access. The company faces ongoing patent expirations and competitive pressures in key therapeutic areas, which could impact revenue stability in the near term.

Analysts highlighted potential growth drivers, including cost-cutting measures and new product launches. Morgan Stanley recently raised its price target for Pfizer, signaling confidence in its long-term resilience. However, the EU’s legal challenge over Paxlovid’s pricing could introduce regulatory uncertainties, affecting profitability if not resolved favorably.

Backtest results indicate Pfizer’s YTD return of -1.65% underperformed the S&P 500’s +9.84%, while its 1-year return of -7.74% lagged behind the benchmark’s +15.53%. Over three years, the stock declined 36.86% compared to the S&P 500’s 60.28% gain, reflecting structural challenges in its core markets.